Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.62 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 6/20 | 0.59 |
| ▸ | CACNB1 | Q02641 | 6/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469112 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1CACNA1GTDP1POLB | |
| SCHEMBL16705050 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1CACNA1GTDP1POLB | |
| SCHEMBL26330969 | 0.83 | CACNA2D1 (0.81) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL26330804 | 0.82 | HPGD (0.72) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4388697 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1POLBCHRM1 | |
| SCHEMBL13004966 | 0.77 | NPSR1 (0.67) | KDM4EALDH1A1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL5268034 | 0.77 | CACNA1G (1.00) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C | |
| Hydrochloric Acid SCHEMBL4380646 | 0.76 | KDM4E (0.55) | KDM4EALDH1A1POLBCHRM1 | |
| SCHEMBL13005947 | 0.76 | CHRM3 (0.61) | KDM4EALDH1A1POLBCHRM1 | |
| SCHEMBL8268615 | 0.76 | CACNA2D1 (0.71) | CACNA1GCACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670775-A4 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-04-22 | — | — | EP | claimed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| JP-2007504174-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1670775-A1 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-06-21 | — | — | EP | claimed |
| WO-2005021523-A1 | PIPERAZINE SUBSTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-03-10 | — | — | WO | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | KDM4E 3155/4885ALDH1A1 3720/4885CACNA1G 4/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | KDM4E 3858/4885ALDH1A1 4513/4885CACNA1G 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.